Sublingual tablet with fast onset of action for the treatment of breakthrough pain in cancer patients.
|Description||Abstral™ provides fast and effective treatment of breakthrough pain in cancer patients. Abstral™ combines quick-dissolving sublingual tablet technology and the analgesic, fentanyl.|
|Indication||Breakthrough cancer pain.|
|Strengths||100, 200, 400 μg|
EMA approved June 2008; FDA approved January 2011.
|Business Partner||Kyowa Hakko Kirin Co. Ltd|